A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study
Ni A. Khin·Jaskaran Singh·Tingting Ge·Hans Klein·Jacob S. Ballon·Satjit Brar·Philip D. Harvey·Joshua T. Kantrowitz·Richard S. E. Keefe·Mahnaz Asgharnejad·Venkatesha Murthy·Eiry Roberts·Reuben H. Fan
Abstract The phase 2 ERUDITE (NCT05182476) study evaluated the efficacy and safety of luvadaxistat, a selective ᴅ-amino acid oxidase inhibitor, for cognitive impairment associated with schizophrenia. ERUDITE was a randomized, double-blind, placebo-controlled, parallel-group study in adults with schizophrenia receiving background antipsychotic therapy. Following a 2-week placebo run-in, participants were randomized 2:1:1 to receive placebo, luvadaxistat 20 mg, or luvadaxistat 50 mg once daily for